A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Inclusion Criteria:

• Physician-diagnosed PAR.

• Has a positive skin prick test (SPT) with indoor allergens and/or positiveantigen-specific serum immunoglobulin E (IgE) for indoor allergens ≥0.70 kU/L,utilizing a validated assay (central laboratory).

• A dermatographic participant who has a known history of dermatographism oridentified during the SPT may participate in this study with a positive serum IgEtest.

• Participants who have concomitant asthma must be stable in the 3 months prior toscreening using permitted regular asthma treatment.

Exclusion Criteria:

• Have received a dose of lebrikizumab.

• Is currently on allergen immunotherapy. However, individuals who discontinuedsubcutaneous or sublingual immunotherapy (SCIT/SLIT) for ≥3 years prior torandomization are eligible, if they were not on a maintenance allergen immunotherapy (AIT) regimen.

• Have received treatment with any rescue medication during the screening and/orrun-in period.

• Have received treatment with any biologic or systemic immunosuppressants forinflammatory disease or autoimmune disease prior to the baseline visit:

1. B cell-depleting biologics, including rituximab, within 6 months.

2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.

3. Systemic immunosuppressants within 4 weeks prior to baseline.

• Have a history of seasonal worsening of AR and if the seasonal worsening is expectedduring the 4-week run-in period, the first 16 weeks after randomization, or duringthe last 4 weeks of the maintenance period.

• Anticipates significant changes in their daily environmental exposure

• Has a known history of recurrent acute or chronic sinusitis,

• Female participant who is pregnant, breastfeeding or is planning to become pregnantor to breastfeed during the study.